Show Summary Details
Page of

Adrenocortical cancer 

Adrenocortical cancer
Adrenocortical cancer

Rossella Libè

, Lionel Groussin

, Xavier Bertagna

, and Jérôme Bertherat

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2022. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 26 May 2022

Adrenocortical cancer (ACC) is among the most aggressive endocrine tumours with an overall very poor prognosis. Morbidity and mortality can be secondary to steroid hormone excess and/or tumour growth and metastases. This potentially poor outcome justifies the importance of considering malignancy in the man-agement of an adrenal mass. The diagnosis of malignancy in a patient with an adrenal tumour relies on careful investigations of clinical, biological, and imaging features before surgery and path-ological examination after tumour removal. Appropriate man-agement and follow-up by an expert multidisciplinary team is important to improve prognosis and to progress in these rare neoplasms.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.